Seetharama D Jois Selected Research

Therapeutics

1/2023	EGFR trafficking: effect of dimerization, dynamics, and mutation.
1/2020	In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC.
1/2020	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.
1/2020	Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
9/2017	A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seetharama D Jois Research Topics

Disease

18	Neoplasms (Cancer) 05/2023 - 01/2016
6	Lung Neoplasms (Lung Cancer) 05/2023 - 09/2017
3	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2017
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
2	COVID-19 01/2022 - 10/2020
2	Adenocarcinoma of Lung 01/2022 - 01/2020
2	Carcinoma (Carcinomatosis) 01/2021 - 01/2017
2	Adenocarcinoma 01/2020 - 11/2019
2	Colonic Neoplasms (Colon Cancer) 11/2019 - 01/2019
1	Infections 10/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Hypercholesterolemia 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Experimental Arthritis 11/2015
1	Rheumatoid Arthritis 11/2015
1	Autoimmune Diseases (Autoimmune Disease) 11/2015

Drug/Important Bio-Agent (IBA)

8	PeptidomimeticsIBA 05/2023 - 11/2015
7	Peptides (Polypeptides)IBA 01/2022 - 01/2016
5	ErbB Receptors (EGF Receptor)IBA 01/2023 - 11/2019
4	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2015
3	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2023 - 01/2017
3	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2020
3	4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA 01/2020 - 01/2017
3	compound 18IBA 01/2020 - 09/2017
2	Liposomes (Liposome)IBA 05/2023 - 10/2021
2	LigandsIBA 05/2023 - 01/2022
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2021 - 01/2020
1	Cytotoxins (Cytolysins)IBA 05/2023
1	TrehaloseIBA 05/2023
1	Cell Surface ReceptorsIBA 01/2022
1	pyrazoloneIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	QuinazolinonesIBA 12/2021
1	Growth Factor ReceptorsIBA 02/2021
1	AntibodiesIBA 02/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2021
1	Single-Domain AntibodiesIBA 02/2021
1	Cyclic PeptidesIBA 01/2021
1	Anti-HIV Agents (AIDS Drugs)IBA 10/2020
1	Glycoproteins (Glycoprotein)IBA 10/2020
1	Antiviral Agents (Antivirals)IBA 10/2020
1	Nelfinavir (Viracept)FDA Link 10/2020
1	Olive OilIBA 06/2020
1	oleocanthalIBA 06/2020
1	Hormones (Hormone)IBA 01/2020
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	Anaplastic Lymphoma KinaseIBA 01/2020
1	pseurotinIBA 01/2020
1	LuciferasesIBA 01/2020
1	Contrast MediaIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	LDL Receptors (LDL Receptor)IBA 01/2020
1	leucyl- alanyl- arginyl- leucyl- leucyl- threonineIBA 11/2019
1	MethyltransferasesIBA 01/2019
1	N-methyladenosineIBA 01/2019
1	Adenosine (Adenocard)FDA LinkGeneric 01/2019
1	CeramidesIBA 01/2019
1	Codon (Codons)IBA 01/2019
1	6-methyladenineIBA 01/2019
1	RNA Precursors (Precursor, mRNA)IBA 01/2019
1	Mutant Proteins (Protein, Mutant)IBA 01/2019
1	Amino Acids FDA Link 02/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2017
1	AnthracyclinesIBA 01/2017
1	mesoporphyrin IXIBA 01/2016

Therapy/Procedure

5	Therapeutics 01/2023 - 09/2017
1	Drug Therapy (Chemotherapy) 05/2023
1	Ligation 10/2022
1	Precision Medicine 02/2021
1	Immunotherapy 01/2020
1	Intravenous Administration 11/2019
1	Immunomodulation 11/2015